COMBI DIAGNOST R90 טנזניה - אנגלית - Tanzania Medicinces & Medical Devices Authority

combi diagnost r90

mokasi medical system and electronics services ltd, tanzania - diagnostic x-ray systems -

Tolucombi האיחוד האירופי - אנגלית - EMA (European Medicines Agency)

tolucombi

krka, d.d., novo mesto - telmisartan, hydrochlorothiazide - hypertension - telmisartan and diuretics - tolucombi fixed-dose combination (80 mg telmisartan/25 mg hydrochlorothiazide) is indicated in adults whose blood pressure is not adequately controlled on tolucombi 80 mg/12.5 mg (80 mg telmisartan/12.5 mg hydrochlorothiazide) or adults who have been previously stabilised on telmisartan and hydrochlorothiazide given separately.

RECOMBIVAX HB (hepatitis b vaccine- recombinant injection, suspension ארצות הברית - אנגלית - NLM (National Library of Medicine)

recombivax hb (hepatitis b vaccine- recombinant injection, suspension

merck sharp & dohme llc - hepatitis b virus subtype adw hbsag surface protein antigen (unii: xl4hlc6jh6) (hepatitis b virus subtype adw hbsag surface protein antigen - unii:xl4hlc6jh6) - hepatitis b virus subtype adw hbsag surface protein antigen 5 ug in 0.5 ml - recombivax hb® [hepatitis b vaccine, recombinant] is indicated for prevention of infection caused by all known subtypes of hepatitis b virus. recombivax hb is approved for use in individuals of all ages. recombivax hb dialysis formulation is approved for use in adult predialysis and dialysis patients 18 years of age and older. do not administer recombivax hb to individuals with a history of severe allergic or hypersensitivity reactions (e.g. , anaphylaxis) after a previous dose of any hepatitis b-containing vaccine or to any component of recombivax hb, including yeast [see description (11)] . risk summary all pregnancies have a risk of birth defect, loss, or other adverse outcomes. in the us general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4%, and 15% to 20%, respectively. there are no adequate and well-controlled studies designed to evaluate recombivax hb in pregnant women. available post-approval data do not suggest an in

Prepandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics האיחוד האירופי - אנגלית - EMA (European Medicines Agency)

prepandemic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted) novartis vaccines and diagnostics

novartis vaccines and diagnostics s.r.l. - influenza virus surface antigens (haemagglutinin and neuraminidase) of strain a/viet nam/1194/2004 (h5n1) - influenza, human, immunization, disease outbreaks - vaccines, - active immunisation against h5n1 subtype of influenza a virus., this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of the vaccine containing a/vietnam/1194/2004 (h5n1)-like strain., prepandemic influenza vaccine (h5n1) novartis vaccines and diagnostic should be used in accordance with official recommendations.,

Apixaban Combino Pharm 2.5 mg film-coated tablets מלטה - אנגלית - Medicines Authority

apixaban combino pharm 2.5 mg film-coated tablets

combino pharma (malta) ltd. hf60, hal far industrial estate, bbg07, hal far, malta - apixaban - film-coated tablet - apixaban 2.5 mg - antithrombotic agents

Apixaban Combino Pharm 5 mg film-coated tablets מלטה - אנגלית - Medicines Authority

apixaban combino pharm 5 mg film-coated tablets

combino pharma (malta) ltd. hf60, hal far industrial estate, bbg07, hal far, malta - apixaban - film-coated tablet - apixaban 5 mg - antithrombotic agents

Prepandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics האיחוד האירופי - אנגלית - EMA (European Medicines Agency)

prepandemic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted) novartis vaccines and diagnostics

novartis vaccines and diagnostics s.r.l. - influenza virus surface antigens (haemagglutinin and neuraminidase) of strain a/viet nam/1194/2004 (h5n1) - influenza, human - vaccines - active immunisation against h5n1 subtype of influenza a virus.; this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of the vaccine containing a/vietnam/1194/2004 (h5n1)-like strain.; prepandemic influenza vaccine (h5n1) novartis vaccines and diagnostic should be used in accordance with official recommendations.

H-B-VAX II hepatitis B vaccine recombinant 10 microgram/1mL injection pre-filled syringe (thiomersal free) אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

h-b-vax ii hepatitis b vaccine recombinant 10 microgram/1ml injection pre-filled syringe (thiomersal free)

merck sharp & dohme (australia) pty ltd - hepatitis b surface antigen recombinant, quantity: 10 microgram/ml - injection, suspension - excipient ingredients: aluminium; borax; sodium chloride; water for injections - h-b-vax ii is indicated for immunisation against infection caused by all known subtypes of hepatitis b virus. adolescent vaccination is not necessary for children who have received a primary course of hepatitis b vaccine. vaccination is recommended in adults who ar at substantial risk of hepatitis b virus infection and have demonstrated or judged to be susceptible. vaccination of individuals who have antibodies against hepatitis b virus from a previous infection is not necessary.

H-B-VAX II hepatitis B vaccine recombinant preservative-free paediatric 5 microgram/0.5mL אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

h-b-vax ii hepatitis b vaccine recombinant preservative-free paediatric 5 microgram/0.5ml

merck sharp & dohme (australia) pty ltd - hepatitis b surface antigen recombinant, quantity: 5 microgram - injection, suspension - excipient ingredients: borax; water for injections; sodium chloride; aluminium - for use in the immunisation against infection caused by all known subtypes of hepatitis b virus. indications as at 17 november 2000: h-b-vax ii is indicated for immunisation against infection caused by all known subtypes of hepatitis b virus. adolescent vaccination is not necessary for children who have received a primary course of hepatitis b vaccine. vaccination is recommended in adults who are at substantial risk of hepatitis b virus infection and have demonstrated or judged to be susceptible. vaccination of individuals who have antibodies against hepatitis b virus from a previous infection is not necessary.

H-B-VAX II hepatitis B vaccine recombinant 10 microgram/1mL injection vial (thiomersal free) אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

h-b-vax ii hepatitis b vaccine recombinant 10 microgram/1ml injection vial (thiomersal free)

merck sharp & dohme (australia) pty ltd - hepatitis b surface antigen recombinant, quantity: 10 microgram/ml - injection, suspension - excipient ingredients: borax; sodium chloride; aluminium; water for injections - h-b-vax ii is indicated for immunisation against infection caused by all known subtypes of hepatitis b virus. adolescent vaccination is not necessary for children who have received a primary course of hepatitis b vaccine. vaccination is recommended in adults who ar at substantial risk of hepatitis b virus infection and have demonstrated or judged to be susceptible. vaccination of individuals who have antibodies against hepatitis b virus from a previous infection is not necessary.